Hims & Hers Health, Inc. (HIMS)
NYSE: HIMS · Real-Time Price · USD
29.14
-2.78 (-8.71%)
At close: Mar 28, 2025, 4:00 PM
28.94
-0.20 (-0.69%)
After-hours: Mar 28, 2025, 7:59 PM EDT
Hims & Hers Health Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Hims & Hers Health stock have an average target of 38.75, with a low estimate of 22 and a high estimate of 68. The average target predicts an increase of 32.98% from the current stock price of 29.14.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Hims & Hers Health stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 5 | 4 |
| Buy | 0 | 0 | 1 | 1 | 0 | 0 |
| Hold | 6 | 6 | 6 | 5 | 7 | 6 |
| Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Total | 12 | 13 | 14 | 14 | 14 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Sell Maintains $21 → $22 | Sell | Maintains | $21 → $22 | -24.50% | Mar 18, 2025 |
| B of A Securities | B of A Securities | Sell Reiterates $21 | Sell | Reiterates | $21 | -27.93% | Mar 6, 2025 |
| Citigroup | Citigroup | Strong Sell Reiterates $27 | Strong Sell | Reiterates | $27 | -7.34% | Mar 6, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $24 → $39 | Hold | Maintains | $24 → $39 | +33.84% | Feb 26, 2025 |
| Leerink Partners | Leerink Partners | Hold Maintains $24 → $40 | Hold | Maintains | $24 → $40 | +37.27% | Feb 25, 2025 |
Financial Forecast
Revenue This Year
2.32B
from 1.48B
Increased by 56.79%
Revenue Next Year
2.73B
from 2.32B
Increased by 18.10%
EPS This Year
0.52
from 0.53
Decreased by -2.95%
EPS Next Year
0.70
from 0.52
Increased by 36.45%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.5B | 3.2B | 4.2B | ||
| Avg | 2.3B | 2.7B | 3.5B | ||
| Low | 1.9B | 1.9B | 2.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 69.8% | 37.2% | 51.8% | ||
| Avg | 56.8% | 18.1% | 27.0% | ||
| Low | 29.1% | -18.4% | 6.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.86 | 0.96 | 1.43 | ||
| Avg | 0.52 | 0.70 | 1.31 | ||
| Low | -0.02 | 0.35 | 1.19 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 61.8% | 85.0% | 102.6% | ||
| Avg | -2.9% | 36.4% | 86.0% | ||
| Low | - | -31.7% | 68.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.